Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Topline data presented from E.U. phase III study of Wynzora Cream for psoriasis vulgaris

Dec. 20, 2019

Topline data reported from phase II study of ARQ-151 in atopic dermatitis

Dec. 18, 2019

Ustekinumab biosimilar DMB-3115 begins phase I trial

Dec. 16, 2019

Decoding EGFR's skin toxicity

Dec. 16, 2019

Three phase III trials of tralokinumab in atopic dermatitis meet endpoints

Dec. 11, 2019

FDA removes clinical hold on Abeona's phase III VIITAL study of EB-101

Dec. 10, 2019

InMed receives CTA approval for phase I study of INM-755

Dec. 10, 2019

Phase III BE SURE study of bimekizumab in plaque psoriasis meets coprimary endpoints

Dec. 9, 2019

Healthy volunteer safety data reported from phase IIb study of EB-01 in allergic contact dermatitis

Dec. 4, 2019

BiomX completes enrollment in cosmetic clinical study of BX-001 in acne-prone skin

Dec. 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...